|
摘要：
|
|
摘要：目前晚期肝细胞癌（hepatocellular carcinoma，HCC）的治疗手段主要包括
分子靶向治疗、免疫治疗和系统化疗等。晚期HCC的一线治疗手段包括以索拉非
尼、仑伐替尼等为代表的分子靶向治疗以及以阿替利珠单抗、信迪利单抗等为代
表的免疫治疗。无论是分子靶向治疗还是免疫治疗，由于缺乏特异性的靶点标志
物，其治疗效果都有限，且进展及复发率高，因此晚期HCC的后线治疗显得尤为
必要。本文就晚期HCC二线治疗的现状及进展进行综述。
|
|
Abstract: At present, the treatment of advanced hepatocellular carcinoma
(HCC) mainly includes molecular targeted therapy, immunotherapy and systemic
chemotherapy. The first-line systemic regimens of advanced HCC include molecular
targeted therapy represented by sorafenib and lenvatinib, and immunotherapy
represented by atelizumab and sintilimab. Whether molecular targeted therapy or
immunotherapy, due to the lack of specific biomarkers, the efficacy is limited, and
the rate of progression and recurrence is high, so the post-line treatment of advanced
HCC is particularly necessary. This article reviewed the current status and progress of
second-line treatment for advanced HCC.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|